In October 2016 Dr. Avnur Joined Quark Venture Inc. as Chief Scientific officer and partner at Quark Venture Inc., a venture
Yaron Breski is a Founding Partner at RMGP Biopharma Investment Fund and Managing Director at RM Global. Mr.
Ohad joined Pontifax in 2009 and is involved in identifying as well as evaluating new investment opportunities.
Tomer is the co-founder and Chief Executive Officer of Pontifax. He serves as an active board member of many of the
Head of Pharma. Dr. Pini Orbach joined Arkin Holdings in 2010 as Head of its Pharma Division. Dr. Orbach is a member
Michel is a seasoned Venture Capitalist and senior executive investing in MedTech & Biotech, expert in value
Michel is a seasoned Venture Capitalist and senior executive investing in MedTech & Biotech, expert in value building throughout the whole spectrum of tech companies development, with a track record of successful exits of over 1.5 $Bn.
Advisor to CBG Ltd, a multi Billion family office. Former CEO of Hadasit Bio-Holdings (HDST), serves on the BOD of Enlivex, Kahr Medical, Minovia, Innovalve, Omnix, Eximore, TPCera, Epitomee, Meditate, PI Therapeutics, Xenia Ventures and VLX Incubator, served as Chairman of Kahr and on the BOD of Cellcure.
Former Venture Partner at Agate Medical Investments and Managing General Partner at MaC LP VC Funds, with over $100M under management, with significant exits (Lumenis, MST, Endochoice, Peptron).
Former Elron’s BD Director, leading the Medical Devices sector.
Established and managed the Israel investment banking activity of ING Barings, served as VP Investment Banking at Cukierman & Co.
During the 90’s served as Economic Consul in Boston, and as Commercial Attaché to South Korea. As Officer (Academic Reserve, Captain Res.) in the IDF Navy, managed the development of advanced Naval systems for the Navy’s elite unit.
Mr. Habib holds a BsC in Aeronautical Engineering from the Technion. He is a graduate from Israel’s foreign service economic cadet school, member of the Technion Alumni “100 Club” and graduate from the Global Executive Program on Negotiation (PON) at Harvard Law School.
Head of Pharma. Dr. Pini Orbach joined Arkin Holdings in 2010 as Head of its Pharma Division. Dr. Orbach is a member of the board in several of its pharmaceutical companies, including UroGen Pharma and Quiet Therapeutics, from which he shares his extensive hands-on drug development and business experience. He originally gained his foundation in US based companies such as, Arisaph Pharmaceuticals and Epix Pharmaceuticals (NASDAQ, EPIX), as well as Israeli-based companies such as, cCAM BioTherapeutics – a cancer immunotherapy company, which was sold to Merck in 2015 for $605M. He holds a Ph.D. from the Department of Physiology and Functional Genomics, University of Florida, and was a postdoctoral fellow at the Cardiovascular Research Center, Harvard Medical School – Massachusetts General Hospital.
Tomer is the co-founder and Chief Executive Officer of Pontifax. He serves as an active board member of many of the funds’ portfolio companies, assuming a special responsibility for strategic planning. Among other positions, Tomer serves as a board member at Eloxx Pharmaceuticals, LogicBio Therapeutics, Cathworks and V-Wave. During the 10 years prior to establishing Pontifax, he held senior management positions at top Israeli financial institutions, playing a key role in investing in, nurturing and managing technology-driven startups. Tomer holds a B.A. in Economics from Harvard University and a J.D. from Harvard Law School.
Ohad joined Pontifax in 2009 and is involved in identifying as well as evaluating new investment opportunities. Ohad focuses on early-stage projects and oversees scouting, due diligence and company formation. He also supports development and business development activities within our early-stage portfolio companies. Ohad serves as a director in Metabomed, Pi Therapeutics, Keros Therapeutics, Eyevensys and Horama. Ohad obtained his M.S. in Biology from Tel-Aviv University and writes about small and mid-cap biotech stocks on his blog: www.orf-blog.com
Yaron Breski is a Founding Partner at RMGP Biopharma Investment Fund and Managing Director at RM Global. Mr. Breski holds over 14 years of experience in healthcare, finance, and business development, and is focused on developing and executing novel models to financing life science innovation. Previously, Mr. Breski served as a senior executive of business development at Rosetta Genomics, a biotech company focusing on cancer diagnostics. Before that Mr. Breski was part of the US Strategic Planning group at Novartis, and before with Booz Allen’s Healthcare group in New York. Mr. Breski holds a B.Sc. in Biology, Magna Cum Laude, research track for honors students from the Tel Aviv University; and an M.B.A from The Wharton School, University of Pennsylvania.
In October 2016 Dr. Avnur Joined Quark Venture Inc. as Chief Scientific officer and partner at Quark Venture Inc., a venture investment fund focused on life sciences investments.
Dr. Avnur was the Global Head of Academic Innovation, Roche Partnering from 2009 until October 2016. In this role she was responsible for creating relationships with the world’s leading academic institutions and world class innovators, gaining Roche early access to innovation. Dr. Avnur has established agreements with over 20 universities, started more than 100 academic programs. Ds. Avnur created the ROADS (Roche Alliance with Distinguished Scientists) program, a model for collaboration between Industry and Academic institutions. Dr. Avnur found and performed scientific evaluation of opportunities and in-licensing leads mainly in early stage throughout the world. From these she has created nine start-up companies. Several of these innovations were recognized as Game Changing Innovation at Roche.
Preceding her current academic innovation leadership role, Dr. Avnur moved to Roche Partnering group (Basel, Switzerland, 2006) and assumed responsibility for scientific evaluations of partnering opportunities and joined the “Finder” group for Biomarkers for all therapeutic areas. She acted as Liaison between Pharma and Diagnostic Divisions’ Biomarkers activities, and contributed to the PHC (Personalized Health Care) initiative.
Prior to her partnering roles, Ms. Avnur worked in diagnostics and pharmaceuticals research and development for nearly 20 years. Her focus areas included diagnostics, the finding of biomarkers in various therapy areas (including Asthma and COPD, transplant genitourinary, CNS, arthritis, transplant and hepatitis C.), preclinical pharmacology (osteoporosis), overseeing the advancement of compounds from the bench into the clinic.
Major scientific achievements include advancing three compounds (a PTHrP analog and two vitamin D analogs, for the treatment of postmenopausal osteoporosis) from early exploratory discovery research to the clinic.